Optimizing Treatment Strategies in R/R Hepatocellular Carcinoma - Episode 5

Transitioning From Locoregional to Systemic Therapy

, , ,
EP. 1: HCC Etiologic Risk Factors and Global Prevalence
EP. 2: HCC Global Screening Programs for At-Risk Populations
EP. 3: The Evolving Role of Medical Oncologists and Hepatologists
EP. 4: HCC Diagnosis and Prognosis
Now Viewing
EP. 5: Transitioning From Locoregional to Systemic Therapy
EP. 6: HCC Treatment Algorithm: Asia and Europe
EP. 7: Frontline Decision Factors for Metastatic Disease
EP. 8: Phase 3 IMbrave150 Trial
EP. 9: Frontline Therapy: Promising I/O Combinations
EP. 10: Frontline I/O: Clinical Trial Overviews
EP. 11: R/R HCC: Second-Line Options
EP. 12: Second-Line Sequencing After IMbrave150 Regimen
EP. 13: Second-Line Therapy: Monoclonal Antibody
EP. 14: REACH and REACH2 Trial Overview
EP. 15: I/O Second-Line Treatment
EP. 16: Metastatic HCC Unmet Needs
EP. 17: Emerging Therapies for HCC Management